We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $1.93B
1-Year Est. Return 134.74%
This Fund
S&P 500
This Quarter Est. Return
+13.92%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$1.64B
AUM Growth
+$104M
Cap. Flow
+$33.3M
Cap. Flow %
2.04%
Top 10 Hldgs %
51.14%
Holding
80
New
16
Increased
18
Reduced
19
Closed
17

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$67.2M
2
ABBV icon
AbbVie
ABBV
+$49.4M
3
BSX icon
Boston Scientific
BSX
+$43.6M
4
UTHR icon
United Therapeutics
UTHR
+$35.4M
5
LLY icon
Eli Lilly
LLY
+$34.4M

Top Sells

Rank Stock Value
1
SYK icon
Stryker
SYK
+$111M
2
MDT icon
Medtronic
MDT
+$50.6M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$47.6M
4
BPMC
Blueprint Medicines
BPMC
+$23.1M
5
BMY icon
Bristol-Myers Squibb
BMY
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 89.89%
2 Miscellaneous 10.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
76
PUT
Invesco QQQ Trust
QQQ
$489B
– –
-175,000
Closed -$82.1M
SLNO
77
PUT
DELISTED
Soleno Therapeutics
SLNO
– –
-529,300
Closed -$37.8M
SRPT icon
78
Sarepta Therapeutics
SRPT
$2.33B
– –
-327,618
Closed -$20.9M
SYK icon
79
Stryker
SYK
$106B
– –
-298,567
Closed -$111M
VIR icon
80
Vir Biotechnology
VIR
$1.83B
– –
-83,010
Closed -$538K
1 2 3
4

Similar funds

GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
EK
Evensky & Katz Coral Gables, Florida $1.94B AUM 22.01% 1-Year Est. Return
CTI
Community Trust & Investment Versailles, Kentucky $1.94B AUM 29.99% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
P3I
Progeny 3 Inc Kirkland, Washington $1.94B AUM 19.13% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $1.94B AUM 48.68% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return

Sofinnova Investments's Q2 2025 Portfolio in Review

As of Q2 2025, Sofinnova Investments held 80 positions worth $1.64B, up 6.8% from $1.53B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Sofinnova Investments's Q2 2025 filing shows 16 new, 18 increased, 19 reduced and 17 closed positions. Its largest new stake was AbbVie: 265,850 shares worth $49.3M. The largest sale was Stryker, an estimated $111M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier, followed by Miscellaneous.

  • Sofinnova Investments's largest Q2 2025 buy was AbbVie: 265,850 shares worth $49.3M.
  • Sofinnova Investments added most to Gilead Sciences in Q2 2025, an estimated $67.2M increase.
  • Sofinnova Investments's biggest Q2 2025 reduction was PTC Therapeutics, cutting an estimated $9.66M.
  • Sofinnova Investments fully exited Stryker in Q2 2025, selling an estimated $111M.
  • Sofinnova Investments's ten largest holdings make up 51% of its $1.64B portfolio in Q2 2025.
  • Sofinnova Investments opened 16 new positions and closed 17 in Q2 2025.
  • Sofinnova Investments's portfolio value rose 6.8% quarter-over-quarter to $1.64B.

Based on Sofinnova Investments's 13F filing for Q2 2025, filed 14 Aug 2025.